. 2016 Mar 31;114(8):897–904. doi: 10.1038/bjc.2016.51

Table 1. Absolute and percentage changes (mean±s.d.) in perfusion and R ₂* for SW1222 metastases treated with OXi4503 (n=6), LS174T metastases treated with OXi4503 (n=3) and SW1222 metastases given saline control (n=5).

	SW1222+OXi4503	LS174T+OXi4503	SW1222+Saline
Perfusion
Tumours (ml g⁻¹ min⁻¹)	−0.49±0.44	0.04±0.23	−0.17±0.31
%	−43±33***	61±152	−16±39*
Liver (ml g⁻¹ min⁻¹)	−0.35±0.28	−0.14±0.45	−0.54±0.28
%	−12±12	−10±27	−26±15
R₂*
Tumours (s⁻¹)	5±28	13±12	11±16
%	0±26	28±25***	6±10
Liver (s⁻¹)	12±10	16±10	8±12
%	9±11	13±11	5±7

The internal control of the liver has been included for each group. Stars denote the significance determined by Wilcoxon tests (*P<0.05, **P<0.01, ***P<0.001).

Table 1. Absolute and percentage changes (mean±s.d.) in perfusion and R 2* for SW1222 metastases treated with OXi4503 (n=6), LS174T metastases treated with OXi4503 (n=3) and SW1222 metastases given saline control (n=5).

Table 1. Absolute and percentage changes (mean±s.d.) in perfusion and R ₂* for SW1222 metastases treated with OXi4503 (n=6), LS174T metastases treated with OXi4503 (n=3) and SW1222 metastases given saline control (n=5).